Merck & Co., Inc. (NYSE:MRK)'s talks to buy cancer-drug maker Seagen Inc. (NasdaqGS:SGEN) have stalled for now, threatening what would be the pharmaceutical giant's biggest deal in more than a decade, according to people familiar with the matter. The companies have so far failed to agree on a price, said the people, who asked not to be identified because the information was private. The talks could still resume and possibly yield an agreement, the people said.
Market Closed -
Other stock markets
|
Pre-market 09:29:15 am | |||
125.4 USD | +0.25% | 125.1 | -0.25% |
Apr. 15 | Zacks Adjusts Price Target on Merck & Company to $132 From $128 | MT |
Apr. 11 | Merck & Co Receives a Shareholder Proposal from The Bahnsen Family Trust | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.00% | 318B | |
+28.79% | 676B | |
+23.97% | 554B | |
-7.64% | 349B | |
+5.99% | 291B | |
+2.92% | 210B | |
-0.24% | 204B | |
-9.86% | 194B | |
-11.71% | 144B | |
-8.32% | 142B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck’s Reportedly Talks to Acquire Seagen Hit Snag, Threatening Mega Pharma Deal